`
`In re Application of:
`
`Date: April 9, 2021
`
`BIO-RAD LABORATORIES, INC.
`
`Conf. No.: 2522
`
`Inventors
`
`Serial No.
`
`Filing Date
`
`For
`
`:
`
`:
`
`John F. Regan etal.
`
`16/235,996
`
`GroupArt Unit: 3600
`
`December 28, 2018
`
`ANALYSIS OF NUCLEIC ACIDS
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`
`Commissioner:
`
`SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
`UNDER 37 C.F.R. §§ 1.56, 1.97, and 1.98
`
`Applicant is submitting this Supplemental Information Disclosure Statement pursuant
`
`to 37 C.F.R. §§ 1.56, 1.97, and 1.98 to disclose to the U.S. Patent and Trademark Office
`
`the patents, publications, applications, and/or other references listed on the enclosed,
`
`completed PTO- PTO/SB/08a form(s). The filing of
`
`this Supplemental
`
`Information
`
`Disclosure Statement (IDS) should not be construed as a representation that a search has
`
`been made or as an admission that the listed references are prior art for this application.
`
`Applicants respectfully request that the listed references be expressly considered during
`
`prosecution of the application, and that the references be made of record therein and
`
`appear among the “references cited” on any patents issuing therefrom.
`
`CONTENT OF DISCLOSURE
`
`This Supplemental
`
`Information Disclosure Statement
`
`includes 48 pages total of
`
`PTO/SB/08a forms. However,
`
`it does not include copies of the references listed on the
`
`forms, either because, as permitted under 37 C.F.R. § 1.98(d), copies already were
`
`Page1of2 -
`
`SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT;
`Serial No. 16/235,996; Atty. Docket No. QLI367DIVCON
`
`
`
`submitted to, or cited by, the U.S. Patent and Trademark Office in an earlier U.S. application
`
`(Serial No. 14/848,311, filed September 8, 2015; now U.S. Patent No. 10,167,509, and
`
`Serial No. 13/385,277, filed February 9, 2012; now U.S. Patent No. 9,127,312) that is relied
`
`on here for priority, or because, as permitted under 37 C.F.R. §1.98(a), this application was
`
`filed on or after July 1, 2003 and the references are U.S. patents or published U.S. patent
`
`applications.
`
`TIMING OF DISCLOSURE/ FEE INFORMATION
`
`This Supplemental Information Disclosure Statementis being filed, to the best of the
`
`undersigned’s knowledge, either (1) before the mailing of a first Office action on the merits,
`
`or (2) before the mailing of a first Office action after the filing of a request for continued
`
`examination under 37 C.F.R. § 1.114. Therefore, in accordance with 37 C.F.R. § 1.97(b), no
`
`fee or statement under 37 C.F.R. § 1.97(e) is required.
`
`Please contact the undersigned attorney of record, or his associate, Stan Hollenberg
`
`(Reg. No. 47,658), both at (503) 224-6655, with any questions regarding this Supplemental
`
`Information Disclosure Statement or the associated application.
`
`Respectfully submitted,
`
`KOLISCH HARTWELL, P.C.
`
`CERTIFICATE OF ELECTRONIC FILING
`
`/ James R. Abney /
`James R. Abney
`| hereby certify that this correspondenceis
`Reaistration No. 42.253
`being submitted to the U.S. Patent and
`Cuctorner No 152796
`Trademark
`Office
`via
`the
`EFS-Web
`520 S.W. Yamhill Street, Suite 300
`Electronic Filing System on April 9, 2021.
`
`
`_____WesleyVanDerVeen/Portland, Oregon 97204
`Wesley Van Der Veen
`Telephone: (503) 224-6655
`Facsimile: (503) 972-9115
`Attorney for Applicant
`
`Page2o0f2
`
`-
`
`SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT;
`Serial No. 16/235,996; Atty. Docket No. QLI367DIVCON
`
`